Upcoming Immuno Events

Immuno UK: In-Person

29 - 30 September 2022 |

London, UK

29 - 30 September 2022

London, UK

Designing & delivering innovative immunotherapies to transform cancer care.

Immuno US: In-Person

03 - 04 October 2022 |

San Diego, USA

03 - 04 October 2022

San Diego, USA

Discuss the latest strategies to harness the immune system for the development of innovative therapeutics

Tumour Microenvironment: In-Person

01 - 02 November 2022 |

Berlin, Germany

01 - 02 November 2022

Berlin, Germany

Immuno UK: In-Person

March 2023 |

London, UK

March 2023

London, UK

More Information Coming Soon

Natural Killer Cell Symposium

May 2023 |

EDT (UTC-4)

May 2023

EDT (UTC-4)

More Information Coming Soon

Tumour Microenvironment: Online

September 2023 |

BST (UTC+1)

September 2023

BST (UTC+1)

More Information Coming Soon

Immuno US: In-Person

October 2023 |

San Diego, USA

October 2023

San Diego, USA

More Information Coming Soon

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing the immuno industry today.

Attendance to our Discussion Groups is available to members of our Immuno Member Community. For more information about Membership, please click here.

Bispecific Antibodies For Cancer Immunotherapy

Taking place on 23 September 2022 | 10:00 (UTC+1)

Discussion Leaders:

  • Xiaofeng Zhao, Senior Director of Discovery Biology, Simcere Pharma
  • Weifeng Liu, Principal Scientist, Pfizer

Discussion topics:

  • Antibody engineering- modalities for IO
  • Recent approvals for bispecific antibodies- efficacy and safety
  • Increasing efficacy, decreasing toxicity
  • Target selection for bispecific antibody and the logic underlying the selections
  • Indication selection and future clinical positioning for bispecific antibodies
  • Biology challenges and MoA studies for bispecific antibodies
Targeting the Tumour Microenvironment

Taking place on Monday 24 October 2022 | 15:00 (UTC)

Discussion Leader:

  • Nagy Habib, Head of R&D and CMO, MiNA Therapeutics

Topics:

  • Is there a blood test that could tell you whether a tumour is myeloid rich?
  • Do you need to neutralise all the components of the tumour microenvironment (cancer associated fibroblasts, macrophages, dendritic cells, etc), or is one component enough?
  • How to target cancer associated fibroblasts?
Engineering & Translational Strategies to Develop Oncolytic Virus Immunotherapy

Taking place Monday 28 November | 16:00 (UTC)

Discussion leaders:

  • Aldo Pourchet, Co-founder of Omios Biologics
  • David Krige, Vice President of Translational Medicine, Psioxus
  • Abhisek Mitra, Senior Scientist, AstraZeneca

Introduction:

  • What is the state of the field now?

Discussion topics:

  • Molecular tropism and Immuno oncology tumour models; exploring the efficacy and predictivity of pre-clinical tumour models
  • Delivering the oncolytic viruses to the tumour sites Is IV delivery important for the success of the field? And what are the different options?
  • Challenges to oncolytic virus replication and spreading within the tumour mass Is IT delivery effective?
  • Oncolytic viruses or vaccine vectors? Do they have to replicate?
    • Which is more important – oncolysis or anti-cancer immune stimulation?
  • Do we need to use vectors for delivery of therapeutic transgenes?
    • And do you need transgenes or is the vector enough?
  • Combination strategies
    • Are these therapeutics going to be active as monotherapy, or will they need to be used in combination?

Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.

Previous Discussion Groups

Discussion Topics:

  • How to make cell therapies more accessible
  • Expanding the range of antigens targeted in the solid tumour environment
  • “Armouring” therapeutic cells for solid tumours
  • Other specific challenges with targeting solid tumours

Discussion Leaders:

  • Michael Zaiac, Head of Medical Affairs Oncology Region Europe, Novartis

  • Paul Rennert, Acting CEO, CSO, Aletabio

Discussion Topics:

  • Presentation: “Risk Assessment and Bioanalytical Strategy to Assess Immunogenicity for Novel Biologics”, by Vibha Jawa, Executive Director at Bristol Myers- Squibb    
  • Developing robust immunogenicity prediction assays for  novel modalities  
  • Considerations for assay format, controls, variation and acceptance criteria  
  • Assessing immunogenicity of IO new therapeutic modalities 

Discussion Leaders:

  • Vibha Jawa, Executive Director, Bristol Myers- Squibb 
  • Garrett Mullins, Senior Director, Eli Lilly 

Ten-minute Introduction from our discussion group leaders:

  • Where we have come from—Old-fashioned ways of treating autoimmune disease
  • Where we are now—The prevalence of inhibiting the immune system, challenges, and weaknesses
  • What’s next? The ‘Brave New World’ of immunology—Re-education of the immune system, benefits, and challenges

Discussion Topics:

  • Inhibition vs re-education of the immune system
  • What novel technologies in the field are emerging?
  • What challenges are scientists facing?

Discussion Leader:

  • Paul Eggleton, Senior Director of Immunology at RevoloBio
  • Roly Foulkes, Chief Scientific Officer at RevoloBio

April 2022

  • Presentation: ‘The Value of In Vivo Imaging in the Clinical Development of IO Drugs,’ by Ian Wilson, Chief Executive Officer at ImaginAb
  • Discovering and validating relevant biomarkers to facilitate rapid novel immunotherapy development 
  • Utility of biomarkers in preclinical and clinical drug development 
  • Unmet market needs: improving clinical translation and pharmacodynamic response 

Discussion Leaders:

  • Ian Wilson, Chief Executive Officer at ImaginAb
  • John Rossi, Head of Translational Medicine, SVP Research at Cero Therapeutics 

March 2022

  • Presentation: “What are the regulatory changes going to be in Europe and the UK”?, by Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca
  • Overcoming regulatory hurdles in IO 
  • Assessing the type of cancer to which immunotherapy will be most beneficial and implementing it in a personalised approach 
  • Exploring the evolution of effective precision immunotherapies 
  • Optimising response and minimising resistance 

Discussion Leaders:

  • Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca 
  • Roy Milner, Associate Regulatory Affairs Director, AstraZeneca  

February 2022

Discussion Topics:

  • Presentation: The Opportunities and Challenges of Preclinical Modelling, by Bonnie Hammer, Senior Vice President, R&D at Inverna   
  • Aligning goals with technologies in preclinical oncology studies 
  • Integrative tumour modelling approaches 
  • Decreasing rate of translational & clinical failures through advanced models

     

Discussion Group Leaders:

  • Bonnie Hammer, Senior Vice President, R&D at Inverna 
  • Pellin Candarlioglu, Cell Biologist/ Bioengineer, Complex In Vitro Models, GSK

October 2021

Join us for a one hour discussion on understanding the tumour microenvironment with advanced technologies. Our live event aims to bring together key opinion leaders discussing cutting-edge research into the area: from markers through to state of the art technologies to understanding immune response through to cell types of interests in tumour indications, do not miss out on attending the session to stay at the forefront of research.

Panel Discussion: Peripheral Markers To Help Understand The Tumour Microenvironment

  • What are the markers for the tumour microenvironment? 
  • Technologies for understanding immune response 
    – Multiplex technologies 
    – Multi-omics technologies 
  • Cell types of interests in tumour indications

Moderator: Paul Jones, Biomarkers Lead, UCB

Panellists:

John Rossi, Senior Vice President and Head of Translational Medicine, Cero Therapeutics 

Siddha Kasar, Clinical Translational Lead of Cell Therapies, Takeda 

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login